Hemisphere Energy (HME) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hemisphere Energy in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HME shares.
View HME analyst ratings or view top-rated stocks.

1 analysts have issued twelve-month price targets for Hemisphere Energy's stock. Their HME share price forecasts range from C$1.45 to C$1.45. On average, they anticipate the company's share price to reach C$1.45 in the next year. This suggests a possible upside of 16.0% from the stock's current price.
View analysts price targets for HME or view top-rated stocks among Wall Street analysts.

Hemisphere Energy's stock was trading at C$1.31 at the beginning of the year. Since then, HME stock has decreased by 4.6% and is now trading at C$1.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 17th 2023.
View our HME earnings forecast.

Hemisphere Energy Co. (CVE:HME) released its earnings results on Thursday, April, 20th. The company reported $0.03 earnings per share (EPS) for the quarter. The business earned $19.56 million during the quarter. Hemisphere Energy had a trailing twelve-month return on equity of 52.17% and a net margin of 30.19%.

Hemisphere Energy (CVE:HME) pays an annual dividend of C$0.10 per share and currently has a dividend yield of 7.81%. HME has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 45.45%. This payout ratio is at a healthy, sustainable level, below 75%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemisphere Energy investors own include Anavex Life Sciences (AVXL), Arrowhead Pharmaceuticals (ARWR), Biopharmx (BPMX), Galmed Pharmaceuticals (GLMD), Melinta Therapeutics (MLNT), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN), Quotient (QTNT), Rexahn Pharmaceuticals (REXN) and ADMA Biologics (ADMA).

Hemisphere Energy trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HME."

Shares of HME stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

One share of HME stock can currently be purchased for approximately C$1.25.

Hemisphere Energy (CVE:HME) has a market capitalization of C$126.59 million and generates C$75.04 million in revenue each year. The company earns C$22.66 million in net income (profit) each year or C$0.22 on an earnings per share basis.

Hemisphere Energy's mailing address is 1055 Hastings St W Suite 2000, VANCOUVER, BC V6E 2E9, Canada. The official website for the company is www.hemisphereenergy.ca. The company can be reached via phone at +1-604-6859255.